The ALICE study is planning to compare the therapeutic effect between atezolizumab (PD-L1 inhibitor) plus immunogenic chemotherapy (liposomal doxorubicin + cyclophosphamide) and immunogenic chemotherapy alone on metastatic triple-negative breast cancer (73). This evidence concerns the gene CD274 and triple-negative breast carcinoma.